NDA 213006 · Sumitomo Pharma Am
Gemtesa
Vibegron · Oral · beta3-Adrenergic Agonist
NovelLast checked: Nov 20, 2026Latest source record: Dec 18, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Dec 23, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
15
8 Phase 3, 2 recruiting
FAERS reports
8,828
2,702 serious, 462 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 1, 2025.
GEMTESA is a beta-3 adrenergic agonist indicated for the treatment of: overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. ( 1.1 ) overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH). ( 1.2 ) 1.1 Overactive Bladder in Adults GEMTESA ® is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. 1.2 Overactive Bladder in Adult Males with Benign Prostatic Hyperplasia (BPH) GEMTESA is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH).
Mechanism: Vibegron is a selective human beta-3 adrenergic receptor agonist. Activation of the beta-3 adrenergic receptor increases bladder capacity by relaxing the detrusor smooth muscle during bladder filling.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 18, 2024 Supplement 11 · Efficacy LabelLetter
- Dec 23, 2020 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- GEMTESA · VIBEGRON 75MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vibegron" as an intervention, any sponsor and status, largest first.
- A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)Pivotal-lookingCompleted
Urovant Sciences GmbHIndustry
NCT03492281 · 1,530 participants · Start Mar 26, 2018 · Primary completion Jan 10, 2019
Drug: vibegron; Vibegron placebo and 2 more · For: Overactive Bladder
Sites: Birmingham, Alabama; Gulf Shores, Alabama; Huntsville, Alabama · 215 sites in all
- A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01314872 · 1,395 participants · Start Mar 31, 2011 · Primary completion Oct 22, 2012
Drug: Vibegron; Tolterodine ER and 2 more · For: Urinary Bladder, Overactive
- Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)Pivotal-lookingCompleted
Urovant Sciences GmbHIndustry
NCT03902080 · 1,105 participants · Start Mar 26, 2019 · Primary completion Jun 15, 2023
Drug: Vibegron; Placebo · For: Overactive Bladder
Sites: Homewood, Alabama; Huntsville, Alabama; Mobile, Alabama · 140 sites in all
- An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).Pivotal-lookingCompleted
Urovant Sciences GmbHIndustry
NCT03583372 · 506 participants · Start Jun 14, 2018 · Primary completion Jun 13, 2019
Drug: Vibegron; placebos and 1 more · For: Overactive Bladder
Sites: Mobile, Alabama; Tempe, Arizona; Tucson, Arizona · 107 sites in all
- Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary IncontinencePivotal-lookingActive, not recruiting
Women and Infants Hospital of Rhode IslandAcademic, hospital or other
NCT05806164 · 432 participants (planned) · Start Jun 6, 2023 · Primary completion Aug 30, 2026
Drug: Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]; OnabotulinumtoxinA 100 UNT [Botox] · For: Urgency Urinary Incontinence
Sites: Birmingham, Alabama; San Diego, California; Washington D.C., District of Columbia · 5 sites in all
- Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic HyperplasiaPivotal-lookingCompleted
Urovant Sciences GmbHIndustry
NCT04103450 · 276 participants · Start Sep 19, 2019 · Primary completion Jul 29, 2022
Drug: Vibegron · For: Overactive Bladder
Sites: Huntsville, Alabama; Lincoln, California; Los Angeles, California · 35 sites in all
- Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel SyndromePivotal-lookingCompleted
Urovant Sciences GmbHIndustry
NCT03806127 · 222 participants · Start Dec 31, 2018 · Primary completion Sep 25, 2020
Drug: Vibegron; Placebo · For: Irritable Bowel Syndrome
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 41 sites in all
- To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive BladderPivotal-lookingCompleted
Jeil Pharmaceutical Co., Ltd.Industry
NCT04917315 · 210 participants · Start May 21, 2020 · Primary completion Aug 18, 2021
Drug: JLP-2002 A mg; Placebo · For: Overactive Bladder
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,194
- diarrhoea440
- headache419
- urinary tract infection392
- urinary retention335
- death332
- fatigue308
- nausea288
- drug effect less than expected285
- inability to afford medication266
- constipation263
- dizziness243
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 6 |
| 2019 | 8 |
| 2020 | 19 |
| 2021 | 211 |
| 2022 | 191 |
| 2023 | 1,842 |
| 2024 | 2,002 |
| 2025 | 2,278 |
| 2026 | 2,266 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Gemtesa (Vibegron)
2024 spending
$945M
Beneficiaries
320,270
1,361,795 claims
Per beneficiary
$2,951
$15.88 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $28,352,679 |
| 2022 | $164,478,183 |
| 2023 | $508,474,527 |
| 2024 | $945,088,935 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis.
He W, Zhang Y, Huang G, et al. · Low Urin Tract Symptoms 2023 · Systematic Review, Network Meta-Analysis
- Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.
He W, Huang G, Cui W, et al. · Int Braz J Urol 2023 · Systematic Review, Network Meta-Analysis
- Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial.
Staskin D, Owens-Grillo J, Thomas E, et al. · J Urol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
Staskin D, Frankel J, Varano S, et al. · J Urol 2020 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and Safety of Vibegron Add-On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α1-Blocker Treatment: A Multi-Center Prospective Randomized Controlled Study (VATON Study).
Yoshida M, Nishino Y, Nagae H, et al. · Low Urin Tract Symptoms 2026 · Randomized Controlled Trial, Multicenter Study
- Comparative Efficacy and Safety of Mirabegron and Vibegron in Female Patients With Overactive Bladder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Liang P, Yu L, Xia B, et al. · Urology 2025 · Systematic Review, Meta-Analysis
Sponsor: Sumitomo Pharma Am
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.